$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000115903613000011 Filed on November 08, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q4
Revenue	$12.50M	$16.01M	$21.79M
YoY Change	-42.65%	200.19%	803.86%
Cost Of Revenue	$3.500M	$683.0K	$700.0K
YoY Change	400.0%	201.37%	600.0%
Gross Profit	$6.266M	$9.342M	$805.9K
YoY Change	677.56%	1811.53%	-66.42%
Gross Profit Margin	50.13%	58.34%	3.7%
Selling, General & Admin	$9.400M	$8.135M	$7.000M
YoY Change	34.29%	44.39%	18.64%
% of Gross Profit	150.02%	87.08%	868.65%
Research & Development	$20.90M	$25.69M	$18.60M
YoY Change	12.37%	31.71%	24.83%
% of Gross Profit	333.55%	274.98%	2308.12%
Depreciation & Amortization	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	0.0%	50.0%
% of Gross Profit	4.79%	3.21%	37.23%
Operating Expenses	$30.30M	$33.82M	$25.50M
YoY Change	18.82%	34.56%	23.19%
Operating Profit	-$24.03M	-$18.49M	-$24.69M
YoY Change	-2.67%	-7.67%	34.94%
Interest Expense	-$700.0K	$850.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net		$52.00K
YoY Change		116.75%
Pretax Income	-$22.00M	-$19.30M	-$4.400M
YoY Change	400.0%	-3.5%	-76.09%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$21.99M	-$19.29M	-$4.406M
YoY Change	399.02%	-3.57%	-76.08%
Net Earnings / Revenue	-175.9%	-120.48%	-20.22%
Basic Earnings Per Share
Diluted Earnings Per Share	-$193.7K	-$171.1K	-$39.15K
COMMON SHARES
Basic Shares Outstanding	114.0M shares	113.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.50M	$65.30M	$99.50M
YoY Change	-28.14%	-25.46%	88.45%
Cash & Equivalents	$27.36M	$17.49M	$99.50M
Short-Term Investments	$44.10M	$47.80M	$0.00
Other Short-Term Assets	$8.400M	$9.100M	$12.80M
YoY Change	-34.38%	-20.18%	54.22%
Inventory	$6.170M	$3.846M	$2.671M
Prepaid Expenses
Receivables	$9.097M	$24.52M	$15.70M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$95.20M	$102.8M	$130.6M
YoY Change	-27.13%	-2.63%	104.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.422M	$4.936M	$3.700M
YoY Change	-7.53%	105.66%	108.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.200M	$2.400M	$400.0K
YoY Change	700.0%
Total Long-Term Assets	$6.598M	$7.327M	$4.100M
YoY Change	60.91%	205.3%	131.53%
TOTAL ASSETS
Total Short-Term Assets	$95.20M	$102.8M	$130.6M
Total Long-Term Assets	$6.598M	$7.327M	$4.100M
Total Assets	$101.8M	$110.1M	$134.7M
YoY Change	-24.45%	1.99%	104.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.135M	$5.592M	$2.272M
YoY Change	38.0%	59.76%	-69.94%
Accrued Expenses	$14.37M	$20.62M	$7.783M
YoY Change	84.61%	157.81%	38.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$5.970M	$0.00
YoY Change
Total Short-Term Liabilities	$24.90M	$39.62M	$18.95M
YoY Change	31.44%	88.68%	9.5%
LONG-TERM LIABILITIES
Long-Term Debt	$49.77M	$26.30M	$29.66M
YoY Change	67.8%
Other Long-Term Liabilities	$1.364M	$921.5K	$0.00
YoY Change		-97.43%	-100.0%
Total Long-Term Liabilities	$51.14M	$921.5K	$29.66M
YoY Change	72.4%	-97.43%	-21.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.90M	$39.62M	$18.95M
Total Long-Term Liabilities	$51.14M	$921.5K	$29.66M
Total Liabilities	$76.04M	$40.55M	$48.61M
YoY Change	56.43%	-28.62%	-11.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$382.1M	-$360.1M	-$298.6M
YoY Change	27.96%		21.86%
Common Stock	$362.0M	$356.6M	$347.4M
YoY Change	4.21%		35.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$19.99M	-$3.486M	$48.86M
YoY Change
Total Liabilities & Shareholders Equity	$101.8M	$110.1M	$134.7M
YoY Change	-24.45%	1.99%	104.88%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q4
OPERATING ACTIVITIES
Net Income	-$21.99M	-$19.29M	-$4.406M
YoY Change	399.02%	-3.57%	-76.08%
Depreciation, Depletion And Amortization	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	0.0%	50.0%
Cash From Operating Activities	-$15.20M	-$12.40M	-$16.90M
YoY Change	-10.06%	-13.29%	25.19%
INVESTING ACTIVITIES
Capital Expenditures	-$1.400M	-$300.0K	-$500.0K
YoY Change	180.0%	50.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$3.300M	$0.00
YoY Change
Cash From Investing Activities	$2.000M	-$300.0K	-$500.0K
YoY Change	-500.0%	50.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	23.10M	2.300M	29.70M
YoY Change	-22.22%	2200.0%	4850.0%
NET CHANGE
Cash From Operating Activities	-15.20M	-12.40M	-16.90M
Cash From Investing Activities	2.000M	-300.0K	-500.0K
Cash From Financing Activities	23.10M	2.300M	29.70M
Net Change In Cash	9.900M	-10.40M	12.30M
YoY Change	-19.51%	-27.78%	-191.79%
FREE CASH FLOW
Cash From Operating Activities	-$15.20M	-$12.40M	-$16.90M
Capital Expenditures	-$1.400M	-$300.0K	-$500.0K
Free Cash Flow	-$13.80M	-$12.10M	-$16.40M
YoY Change	-15.85%	-14.18%	26.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1175594	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1618800	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	62385	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-39742	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5591763	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2271689	USD
CY2012Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	15881227	USD
CY2013Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	24918992	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24521742	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15703087	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-816196	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7783447	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20624501	USD
CY2012Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	984192	USD
CY2013Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8613848	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6680627	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7339722	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15779	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	347314658	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	356449825	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1922393	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6362372	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2303662	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7139998	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1036502	USD
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7300000	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7300000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8600000	shares
CY2013Q3	us-gaap	Assets Assets	110145126	USD
CY2012Q4	us-gaap	Assets Assets	134728397	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	102818028	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	130627935	USD
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	98024269	USD
CY2013Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59672301	USD
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	47818851	USD
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	47803072	USD
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2013Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	47818851	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	47800000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	18279	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	2500	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	89504	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	508990	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1100000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1450000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	2550000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99501264	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17492131	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87614891	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52825527	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	34789364	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-82009133	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112709174	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	113986739	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	113986739	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112709174	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	113987	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	112709	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20005846	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19237280	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61476469	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49146146	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2705633	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	440516	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	682713	USD
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	226635	USD
	us-gaap	Costs And Expenses CostsAndExpenses	69750010	USD
	us-gaap	Costs And Expenses CostsAndExpenses	101410791	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	25364160	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	34507020	USD
	us-gaap	Debt Instrument Covenant Compliance DebtInstrumentCovenantCompliance	September 30, 2013
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	813689	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	861879	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	43845983	USD
CY2013Q3	us-gaap	Deferred Revenue DeferredRevenue	53377944	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7437433	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8891017	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45940511	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	34954966	USD
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	301000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	796000	USD
CY2012Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	286000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	893000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	796163	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	893477	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5351965	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4053590	USD
CY2013Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6610	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2106754	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16070721	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8818655	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2201808	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3469392	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9531961	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2017859	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3021100	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	849936	USD
	us-gaap	Interest Expense InterestExpense	2546515	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2500000	USD
CY2013Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	850000	USD
	us-gaap	Interest Paid InterestPaid	1529438	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	751378	USD
CY2013Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1047274	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	3846290	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	2670696	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1127061	USD
CY2013Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1218406	USD
CY2013Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1580610	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	792257	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134728397	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110145126	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	39623816	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18946153	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	19103970	USD
CY2013Q3	us-gaap	Long Term Debt LongTermDebt	23781955	USD
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	29661680	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2012Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	4618969	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	27667165	USD
CY2013Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	5988262	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5970119	USD
CY2012Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2250791	USD
CY2013Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1603147	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	164544	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a science-driven, biopharmaceutical company committed to making molecules into medicines for patients in need. Our research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, thus enhancing the efficacy and the convenience of other drugs or to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, such as diabetes, oncology and dermatology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the product candidates in our current pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We have one proprietary commercial product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant. Our proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. We currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Pfizer Inc. (“Pfizer”), Baxter Healthcare Corporation (“Baxter”), ViroPharma Incorporated (“ViroPharma”), and Intrexon Corporation (“Intrexon”), with two approved products in Europe, one product candidate which has been submitted for regulatory approval in the U.S. and one product candidate which has been submitted for regulatory approval in Europe as well as several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007. Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these Notes to Condensed Consolidated Financial Statements refer to Halozyme Therapeutics, Inc. and our wholly-owned subsidiary, Halozyme, Inc.</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83073435	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1996447	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49886055	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-873165	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47410906	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34119525	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-20005846	USD
	us-gaap	Net Income Loss NetIncomeLoss	-61492248	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49146146	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-19292368	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59110277	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-49218333	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18493856	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20029837	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1506615	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2162421	USD
CY2012Q4	us-gaap	Other Assets OtherAssets	74944	USD
CY2013Q3	us-gaap	Other Assets OtherAssets	585162	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15779	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	55088	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	921460	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	72187	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23991	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	51424	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	48946616	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	939439	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	873165	USD
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	12752888	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11030184	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12752888	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9139014	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	0	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1891170	USD
	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	400000	USD
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2013Q3	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81476845	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81500000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1596590	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1996447	USD
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12275650	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10381089	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4935928	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3700462	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75714381	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51476329	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25689189	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19503491	USD
CY2012Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	15058163	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-360065896	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298573648	USD
CY2013Q3	us-gaap	Revenues Revenues	16013164	USD
CY2012Q3	us-gaap	Revenues Revenues	5334323	USD
	us-gaap	Revenues Revenues	42300514	USD
	us-gaap	Revenues Revenues	20531677	USD
CY2012Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.61
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14633349	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1427707	USD
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	715354	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10024902	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17833165	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8135118	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5634034	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22990777	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7139998	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6362372	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	6500000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7900000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7100000	shares
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7820000	shares
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-3486305	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	48853719	USD
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112305002	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	110658757	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112554447	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112765155	shares
CY2013Q3	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	15474799	USD
CY2013Q3	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	1512236	USD
CY2012Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	823064	USD
CY2013Q3	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	7931957	USD
CY2012Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	0	USD
CY2012Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	1239050	USD
CY2013Q3	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4496267	USD
CY2013Q3	halo	Additional Achievementof Regulatory Milestones AdditionalAchievementofRegulatoryMilestones	84000000	USD
CY2013Q3	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	68000000	USD
	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.06
CY2013Q3	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.02
CY2012Q3	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.02
	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.06
CY2013Q3	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	397250	USD
CY2012Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	178140	USD
	halo	Available For Sale Securities Sold AvailableForSaleSecuritiesSold	0	USD
CY2012Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	8152602	USD
CY2013Q3	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	5720041	USD
CY2013Q3	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3121834	USD
CY2012Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2274551	USD
CY2012Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1020000	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	114028596	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC

Files In Submission

Name	View Source	Status
0001159036-13-000011-index-headers.html	Edgar Link	pending
0001159036-13-000011-index.html	Edgar Link	pending
0001159036-13-000011.txt	Edgar Link	pending
0001159036-13-000011-xbrl.zip	Edgar Link	pending
ex311q3.htm	Edgar Link	pending
ex312q3.htm	Edgar Link	pending
ex32q3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
halo-20130930.xml	Edgar Link	completed
halo-20130930.xsd	Edgar Link	pending
halo-20130930_cal.xml	Edgar Link	unprocessable
halo-20130930_def.xml	Edgar Link	unprocessable
halo-20130930_lab.xml	Edgar Link	unprocessable
halo-20130930_pre.xml	Edgar Link	unprocessable
halo3q2013-10q.htm	Edgar Link	pending
pipeline10302013final.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2013 Q4 Form 10-Q Financial Statement

#000115903613000011 Filed on November 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2013 Q4 Form 10-Q Financial Statement

#000115903613000011 Filed on November 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo